Bioaffinity Technologies, Inc. (BIAF) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bioaffinity Technologies, Inc., a Delaware corporation, on December 5, 2023, covering events occurring on December 1, 2023. The Company is an emerging growth company with its principal executive offices in San Antonio, Texas. The filing primarily addresses changes to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance changes rather than financial performance.
Material Changes
- Director Appointment: On December 1, 2023, the Board appointed Jamie Platt, Ph.D., as a new director and member of the Compensation Committee. Dr. Platt brings 20 years of leadership in genomics and molecular diagnostics, including recent roles as CEO of Pictor Ltd. and former COO of Personal Genome Diagnostics.
- Director Resignation: On December 1, 2023, Mohsin Y. Meghji resigned from the Board of Directors effective immediately for personal reasons. The resignation was not due to any disagreement with the Company.
- Compensation Arrangement: Dr. Platt will receive an annual fee of $25,000 for Board and committee service. Additionally, she will receive quarterly grants of restricted stock valued at $18,750 on the grant date, vesting after three months.
Guidance, Outlook, and Risks
The filing references a press release issued on December 5, 2023, which contains forward-looking statements protected by the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. The Company explicitly states it undertakes no duty or obligation to update or revise the information contained in this report. No specific financial guidance or new risk factors were disclosed in this filing.
Investor Verification Checklist
- Verify the impact of the Board composition change on the Company's strategic direction in genomics and diagnostics.
- Review the attached press release (Exhibit 99.1) for any additional context regarding the resignation of Mohsin Y. Meghji.
- Confirm the vesting schedule and dilution impact of the restricted stock grants to Dr. Platt under the 2014 Equity Incentive Plan.
- Check subsequent filings for any financial updates, as this 8-K contains no financial data.